Cardiology

Study shows addition of Integrelin to oral platelet therapy more effective at reducing inflammation

Published in Hematology Week, December 19th, 2005

Schering-Plough Corporation (SGP) and Sinai Center for Thrombosis Research of Baltimore announced results from a prospective analysis of the CLEAR Platelets (clopidogrel loading with eptifibatide to arrest the reactivity of platelets) study.

The results showed that adding Integrelin, a potent glycoprotein (GP) IIb-IIIa inhibitor, to a loading dose of clopidogrel, a commonly used oral antiplatelet therapy, produced superior reduction in inflammation in patients undergoing elective percutaneous coronary intervention (PCI) stenting. In this study, the degree of inflammation was assessed by levels of tumor necrosis factor (TNF)-alpha and C-reactive protein (CRP) and other...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hematology Week

Source: Hematology Week (2005-12-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry